Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Market / Stock-market-news/  Indian drug maker stocks exception in Asian rout
BackBack

Indian drug maker stocks exception in Asian rout

Drug makers surged on expectations of higher earnings driven by their expansion in the US and India and faster drug approvals

More than 40% of over-the-counter and generic prescription drugs sold in the US come from India. Photo: BloombergPremium
More than 40% of over-the-counter and generic prescription drugs sold in the US come from India. Photo: Bloomberg

Singapore/Mumbai: The double-digit stock market gains of pharmaceutical giants including Dr. Reddy’s Laboratories Ltd and Wockhardt Ltd stand out in stark relief to the dismal performance of other Asian emerging-market stocks this year.

Their shares have surged on expectations of higher earnings driven by their expansion in the US and India, faster drug approvals, and improved portfolio quality through acquisitions.

Continued strength in the dollar when the Federal Reserve raises interest rates will also boost their income. More than 40% of over-the-counter and generic prescription drugs sold in the US come from India.

In Mumbai trading so far this year, Lupin Ltd has climbed 32%, Dr. Reddy’s 31%, Glenmark Pharmaceuticals Ltd 42% and Wockhardt 29%.

That compares with a 6.9% decline in the Sensex in late trade by Wednesday and a 16% drop in the MSCI Asia Pacific ex-Japan index.

The share price gains in the drug makers were supported by a weaker rupee, which has fallen 5.1% against the greenback this year.

“Large-cap Indian pharma companies are predominantly dollar exposed," said Hemant Bakhru, pharmaceuticals analyst at UBS in Mumbai.

“Emerging-market investors who right now want to avoid risk and invest in assets that are more exposed to the US economy as against emerging markets will naturally choose some of these Indian pharma names."

Asia ex-Japan investors shifted to a “massive" overweight position in pharmaceutical companies in August from “underweight" in the previous month, making the sector their second-biggest exposure, according to Bank of America Merrill Lynch.

They also expanded their overweight positions in India, already their biggest exposure, the bank’s data show. Reuters

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 03 Sep 2015, 09:48 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App